

The Journal of Rheumatology

VOLUME 39: NO. 4

jrheum.org

APRIL 2012

Editorials

- Osteoarthritis, Exercise, and Knee Replacement**
J.F. Fries, B. Bruce, S. Shoor 669
- Exercise and Osteoarthritis: Not Necessarily an All-or-Nothing Proposition!** *A.C. Gelber* 672
- Anti-Citrullinated Peptide/Protein Antibodies and Structural Prognosis of Rheumatoid Arthritis: Quantity Versus Quality** *O. Meyer* 675
- Fibromyalgia and Enthesitis in Psoriatic Arthritis. Time to “Characterize” and “Refine” Clinical Definitions**
J.L. Fernández-Sueiro 677

Reviews

- Apoptosis as a Mechanism of Action of TNF Antagonists in Rheumatoid Arthritis**
D. Makrygiannakis, A.I. Catrina 679
- Relationship Between ACE Insertion/Deletion Gene Polymorphism and SLE/Lupus Nephritis: A Systematic Review and Metaanalysis**
T-B. Zhou, Y-G. Liu, N. Lin, Y-H. Qin, K. Huang, M-B. Shao, D-D. Peng 686

Articles

- ACPA, But Not Its Titer, Is a Predictor of Radiographic Progression and Disease Activity in RA**
K. Shiozawa, Y. Kawasaki, T. Yamane, R. Yoshihara, Y. Tanaka, K. Uto, S. Shiozawa 694
- Infliximab Treatment Increases LVEF in Patients with RA: Assessment of Heart Function by Echocardiography, ET-1, IL-6, and NT-pro Brain Natriuretic Peptide**
P.J. Kotyla, A. Owczarek, J. Rakoczy, M. Lewicki, E.J. Kucharz, P. Emery 701
- Time to Consultation and DMARD Treatment of Patients with RA – Northern Alberta Perspective**
J.A. Nanji, M. Choi, R. Ferrari, C. Lyddell, A.S. Russell . . 707
- Short-term Risk of Total Malignancy and Nonmelanoma Skin Cancers with Certolizumab and Golimumab in Patients with RA: Metaanalysis of Randomized Controlled Trials** *P. Le Blay, G. Mouterde, T. Barnetteche, J. Morel, B. Combe* 712
- Characterization of Patients with Arthritis Referred for Gold Therapy in the Era of Biologics**
J.M. Cheung, D. Scarsbrook, A.V. Klinkhoff 716

- Efficacy and Safety of CE-224,535, an Antagonist of P2X₇ Receptor, in Treatment of Patients with RA Inadequately Controlled by MTX** *T.C. Stock, B.J. Bloom, N. Wei, S. Ishaq, W. Park, X. Wang, et al* 720
- CRP Is a More Sensitive and Specific Marker for Diagnosing Bacterial Infections in SLE Compared to S100A8/A9 and Procalcitonin**
H-A. Kim, J-Y. Jeon, J-M. An, B-R. Koh, C-H. Suh 728
- Construct and Criterion Validity of the Short Form-6D Utility Measure in Patients with SLE**
M.J. Harrison, Y. Ahmad, S. Haque, N. Dale, L-S. Teh, N. Snowden, et al 735
- Occupational Risk Factors for SLE: a Nationwide Study Based on Hospitalizations in Sweden**
X. Li, J. Sundquist, K. Sundquist, B. Zöller 743
- Blood Pressure and Vascular Dysfunction Underlie Elevated Cerebral Blood Flow in SLE** *C. Gasparovic, C. Qualls, E.R. Greene, W.L. Sibbitt Jr, C.A. Roldan* 752
- Differences between Male and Female SLE in a Multiethnic Population**
T.C. Tan, H. Fang, L.S. Magder, M.A. Petri 759
- Are Cognitive and Olfactory Dysfunctions in NPSLE Dependent on Anxiety or Depression?**
S. Cavaco, A. Martins da Silva, E. Santos, E. Coutinho, A. Marinho, I. Moreira, et al 770
- Low Socioeconomic Status Is Associated with Cardiovascular Risk Factors and Outcomes in SLE**
J.W. Maynard, H. Fang, M.A. Petri 777
- Epidemiology of SSc in a Large US Managed Care Population** *D.E. Furst, A.W. Fernandes, Ş.R. Iorga, W. Greth, T. Bancroft* 784
- Clinical Correlates of CENP-A and CENP-B Antibodies in a Large Cohort of Patients with SSc** *M. Hudson, M. Mahler, J. Pope, D. You, S. Tatibouet, R. Steele, et al, Canadian Scleroderma Research Group* 787
- Patient-reported Outcomes in Polymyalgia Rheumatica**
E.L. Matteson, H. Maradit-Kremers, M.A. Cimmino, W.A. Schmidt, M. Schirmer, C. Salvarani, et al 795
- A Clinical Prediction Rule for Lymphoma Development in Primary Sjögren’s Syndrome** *C. Baldini, P. Pepe, N. Luciano, F. Ferro, R. Talarico, S. Grossi, et al* 804
- Detection of HTLV-1 in the Labial Salivary Glands of Patients with Sjögren’s Syndrome: A Distinct Clinical Subgroup?** *S-J. Lee, J.S. Lee, M-G. Shin, Y. Tanaka, D-J. Park, T-J. Kim, et al* 809

Contents continued opposite inside back cover . . .

Performance of the ASAS Classification for Axial and Peripheral Spondyloarthritis in an Established Clinical Cohort: Comparison with Criteria Sets of Amor and the ESSG P.P. Cheung, S. Paternotte, V. Burki, A. Durnez, W. Elhai, I. Fabreguet, et al 816

Preliminary Validation of a Self-reported Screening Questionnaire for Inflammatory Back Pain S.O. Keeling, S.R. Majumdar, B. Conner-Spady, M.C. Battié, L.J. Carroll, W.P. Maksymowych 822

In Vivo Peripheral Blood Proinflammatory T Cells in Patients with AS L. Limón-Camacho, M.I. Vargas-Rojas, J. Vázquez-Mellado, J. Casasola-Vargas, J.F. Moctezuma, R. Burgos-Vargas, L. Llorente 830

Clinical Efficacy of Etanercept Versus Sulfasalazine in AS Subjects with Peripheral Joint Involvement J. Braun, K. Pavelka, C. Ramos-Remus, A. Dimic, B. Vlahos, B. Freundlich, A.S. Koenig 836

Nail Disease in PsA: Distal Phalangeal Bone Edema Detected by MRI Predicts Development of Onycholysis and Hyperkeratosis N. Dalbeth, K. Pui, M. Lobo, A. Doyle, P.B. Jones, W.J. Taylor, F.M. McQueen 841

Construct Validity of the Modified Numeric Rating Scale of Patient Global Assessment in PsA Y-Y. Leung, K-W. Ho, T-Y. Zhu, L-S. Tam, E.W. Kun, E.K-M. Li 844

Identification of the Clinical Features Distinguishing PsA and Fibromyalgia A. Marchesoni, F. Atzeni, A. Spadaro, E. Lubrano, G. Provenzano, A. Cauli, et al 849

Pediatric Rheumatology

Parent and Child Acceptable Symptom State in JIA G. Filocamo, A. Consolaro, B. Schiappapietra, N. Ruperto, A. Pistorio, N. Solari, et al 856

Efficacy and Limitation of Infliximab Treatment for Children with Kawasaki Disease Intractable to IVIG Therapy: Report of an Open-label Case Series M. Mori, T. Imagawa, R. Hara, M. Kikuchi, T. Hara, T. Nozawa, et al 864

Images in Rheumatology

Gouty Arthritis of the Ankle Masquerading as a Talus Fracture M. Yang, B. Guo, D. Liang, D. Shi, L. Yang, J. Cao 868

Correspondence

Posterior Reversible Encephalopathy Syndrome A. Ortiz, S. Roverano, S. Paira 869

Could Increased VEGF Induced by IL-17 Be the Cause of Posterior Reversible Encephalopathy Syndrome in SLE? S.J. Park, K.S. Pai, J.H. Kim, J.I. Shin 870

Reply I.R. Varaprasad, S. Agrawal 871

High-titer Anti-aquaporin-4-IgG-associated Myelitis in Rhupus Syndrome S. Sciascia, D. Roccatello, D. Rossi, A. Russo, M.O. Mereuta, R. Cavallo 871

Reply A.R. Chogle 873

Clarification of the Modified Radiographic Damage Scoring Method for Gout N. Dalbeth, F.M. McQueen 874

Reply J-Y. Choe, S-K. Kim 874

Letters

Clinical Relevance of MEFV Gene Mutations in Japanese Patients with Unexplained Fever K. Migita, H. Ida, H. Moriuchi, K. Agematsu 875

Does a Joint Count Calibration Exercise Make a Difference? Implications for Clinical Trials and Training L.K. Stamp, A. Harrison, C. Frampton, M.M. Corkill 877

Amyloidosis and Giant Cell Arteritis/Polymyalgia Rheumatica K. Legault, A. Shroff, M. Crowther, N. Khalidi 878

Teaching Basic Rheumatology I. Kushner 880

Corrections

Scleritis: A Paradoxical Effect of Etanercept? Etanercept-associated Inflammatory Eye Disease C. Gaujoux-Viala, C. Giampietro, T. Gaujoux, H-K. Ea, C. Prati, P. Orcel, D. Wendling, F. Lioté 881

Dysregulation of the Microvasculature in Nonlesional Non-Sun-exposed Skin of Patients with Lupus Nephritis P.M. Izmirly, M. Shvartsbeyn, S. Meehan, A. Franks, A. Braun, E. Ginzler, S.X. Xu, H. Yee, T. Rivera, C. Esmon, L. Barisoni, J.T. Merrill, J.P. Buyon, R. Clancy 881

Meetings in Rheumatology x